TY - JOUR
T1 - Clinical characteristics and management of neurocysticercosis patients
T2 - a retrospective assessment of case reports from Europe
AU - Stelzle, Dominik
AU - Abraham, Annette
AU - Kaminski, Miriam
AU - Schmidt, Veronika
AU - De Meijere, Robert
AU - Bustos, Javier A.
AU - Garcia, Hector Hugo
AU - Sahu, Priyadarshi Soumyaranjan
AU - Bobić, Branko
AU - Cretu, Carmen
AU - Chiodini, Peter
AU - Dermauw, Veronique
AU - Devleesschauwer, Brecht
AU - Dorny, Pierre
AU - Fonseca, Ana
AU - Gabriël, Sarah
AU - Morales, Maria Ángeles Gómez
AU - Laranjo-González, Minerva
AU - Hoerauf, Achim
AU - Hunter, Ewan
AU - Jambou, Ronan
AU - Jurhar-Pavlova, Maja
AU - Reiter-Owona, Ingrid
AU - Sotiraki, Smaragda
AU - Trevisan, Chiara
AU - Vilhena, Manuela
AU - Walker, Naomi F.
AU - Zammarchi, Lorenzo
AU - Winkler, Andrea Sylvia
N1 - Publisher Copyright:
© International Society of Travel Medicine 2022. Published by Oxford University Press. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Objectives: Neurocysticercosis (NCC) is a parasitic disease caused by the larval stage of the tapeworm Taenia solium. NCC mainly occurs in Africa, Latin America and South-East Asia and can cause a variety of clinical signs/symptoms. Although it is a rare disease in Europe, it should nonetheless be considered as a differential diagnosis. The aim of this study was to describe clinical characteristics and management of patients with NCC diagnosed and treated in Europe. Methods: We conducted a systematic search of published and unpublished data on patients diagnosed with NCC in Europe (2000-2019) and extracted demographic, clinical and radiological information on each case, if available. Results: Out of 293 identified NCC cases, 59% of patients presented initially with epileptic seizures (21% focal onset); 52% presented with headache and 54% had other neurological signs/symptoms. The majority of patients had a travel or migration history (76%), mostly from/to Latin America (38%), Africa (32%) or Asia (30%). Treatment varied largely depending on cyst location and number. The outcome was favorable in 90% of the cases. Conclusions: Management of NCC in Europe varied considerably but often had a good outcome. Travel and migration to and from areas endemic for T. solium will likely result in continued low prevalence of NCC in Europe. Therefore, training and guidance of clinicians is recommended for optimal patient management.
AB - Objectives: Neurocysticercosis (NCC) is a parasitic disease caused by the larval stage of the tapeworm Taenia solium. NCC mainly occurs in Africa, Latin America and South-East Asia and can cause a variety of clinical signs/symptoms. Although it is a rare disease in Europe, it should nonetheless be considered as a differential diagnosis. The aim of this study was to describe clinical characteristics and management of patients with NCC diagnosed and treated in Europe. Methods: We conducted a systematic search of published and unpublished data on patients diagnosed with NCC in Europe (2000-2019) and extracted demographic, clinical and radiological information on each case, if available. Results: Out of 293 identified NCC cases, 59% of patients presented initially with epileptic seizures (21% focal onset); 52% presented with headache and 54% had other neurological signs/symptoms. The majority of patients had a travel or migration history (76%), mostly from/to Latin America (38%), Africa (32%) or Asia (30%). Treatment varied largely depending on cyst location and number. The outcome was favorable in 90% of the cases. Conclusions: Management of NCC in Europe varied considerably but often had a good outcome. Travel and migration to and from areas endemic for T. solium will likely result in continued low prevalence of NCC in Europe. Therefore, training and guidance of clinicians is recommended for optimal patient management.
KW - Clinical epidemiology
KW - Europe
KW - Global Health
KW - NCC management
KW - Neurocysticercosis
KW - One Health
KW - Taenia solium
KW - neglected tropical diseases
UR - https://www.scopus.com/pages/publications/85143796658
U2 - 10.1093/jtm/taac102
DO - 10.1093/jtm/taac102
M3 - Artículo de revisión
C2 - 36222148
AN - SCOPUS:85143796658
SN - 1195-1982
VL - 30
JO - Journal of Travel Medicine
JF - Journal of Travel Medicine
IS - 1
M1 - taac102
ER -